Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
March 04, 2025 07:10 ET
|
Neuronetics
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2025 16:30 ET
|
Neuronetics
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
February 21, 2025 08:30 ET
|
Neuronetics
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025 16:30 ET
|
Neuronetics
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock
February 07, 2025 07:54 ET
|
Neuronetics
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its...
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock
February 06, 2025 16:23 ET
|
Neuronetics
MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In...
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression
January 29, 2025 08:31 ET
|
Neuronetics
MALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Provides Business Update and Issues 2025 Guidance
January 13, 2025 08:00 ET
|
Neuronetics
Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectivelyClosed acquisition of Greenbrook TMS effective as of December 9, 2024Expects full year 2025 pro forma...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2024 16:30 ET
|
Neuronetics
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2024 16:30 ET
|
Neuronetics
MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordance...